Diabetic ChildrenDiabetic ChildNCT07874854
Differential Effects of Aerobic and Circuit Training on Glycemic Regulation in Diabetic Children
A study testing Group A and Group B in people with Diabetic Children, run by Emad Eldin Mohamed at 1 site in Egypt.
Trial summary
Physical activity is recommended for children with type 1 diabetes mellitus (T1DM), yet uncertainty remains regarding the exercise modality that provides the greatest benefit for glycemic control. This study compared the effects of circuit training and aerobic training in children with T1DM. Read more about this study
- Who is it for?
- Ages 6 to 12 years
- Conditions the study is for
- Diabetic Children
- What is being tested?
- Group A and Group B
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteEgypt
- Study dates
- 22 Mar 2026to 12 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 12 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- ● Diabetic children aged 6-12 years.
- Children living in Cairo.
- Diagnosed with Type 1 diabetes mellitus.
Who cannot join
- medical disorders such as cardiac, respiratory, renal, orthopedic, neurological, or other metabolic diseases that may interfere with participation in the exercise program.
Trial locations and contacts
1 site in 1 country.
About this study
Physical activity is recommended for children with type 1 diabetes mellitus (T1DM), yet uncertainty remains regarding the exercise modality that provides the greatest benefit for glycemic control. This study compared the effects of circuit training and aerobic training in children with T1DM.
Read the detailed description
Type 1 diabetes mellitus (T1DM) is a glucose homeostasis illness characterized by the autoimmune destruction of insulin-producing pancreatic β-cells, which gradually leads to insulin insufficiency and hyperglycemia. In addition to raising the risk of both immediate and long-term diabetes-related consequences, inadequate glycemic control throughout the formative years may negatively impact physical development, cardiovascular health, exercise capacity, and psychosocial well-being causing accelerated metabolic derangement, including hyperglycemia, ketoacidosis, hunger, and death (Katsarou et al., 2017). In order to restore and maintain euglycemia, therapy seeks to replicate the activity of the β-cell by exogenously substituting insulin and involves frequent blood glucose monitoring. Dr. Elliott P. Joslin, a visionary pioneer, believed that the best possible outcomes of T1DM treatment are achieved when both patients and families feel empod rather than victimized (Ogleet al., 2025). The prevalence of type 1 diabetes among individuals under the age of 20 in the United States is estimated to be 1.54 cases per 1,000 children. Non-Hispanic white children have the highest prevalence, with 2.0 cases per 1,000, which is 50% higher than black children (1.34 cases per 1,000) and twice as high as Hispanic children (1.0 cases per 1,000). T1DM affects both genders, unlike other autoimmune diseases that typically affect females (Patterson et al., 2019). Most studies have found a seasonal variation in onset in children, with the highest incidence of T1DM occurring in the winter and the lowest during the summer. This observation could be attributed to the greater incidence of viral infections during the winter months, which generate metabolic stress that surpasses the residual β-cell mass's ability to produce enough insulin to sustain euglycemia (Colberg et al., 2016). A susceptibility to T1DM begins at birth with the inheritance of genetic risk factors. Although the majority of newly diagnosed children have no family history of T1DM, unaffected children with a T1DM relative are at a higher risk than the general population. The most significantly related T1DM susceptibility genes are found in the major histocompatibility complex area of chromosome 6, where they most likely direct immune development and allow autoantigens to be presented to autoreactive lymphocytes (Riddell and Iscoe, 2006). The majority of pediatric patients with new-onset T1DM exhibit the characteristic signs of polyuria and polydipsia (69%), with polyphagia and weight loss appearing less commonly (33%). Patients and families usually report that symptoms persist 1 to 2 weeks, but sometimes for several months. These symptoms frequently worsen following an episode of enuresis or the onset of nocturia. Patients usually report vague complaints, such as tiredness, and may experience blurred vision (Yardley et al., 2013). In approximately one-quarter of instances, a patient with new-onset T1DM presents with diabetic ketoacidosis (DKA). These children initially exhibit the same basic signs (polyuria, polydipsia, polyphagia, and weight loss), which progressively worsen.
- Conditions
- Diabetic Children
- Being tested
- Group A, Group B
- Keywords
- Diabetic Children, Aerobic and Circuit Training
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Group AOther
aerobic training program in addition to routine medical care.
Group BOther
aerobic training program in addition to the routine medical and nursing care provided by the diabetic clinic.
| Study group | Role | What they receive |
|---|---|---|
| group A: circuit training program | Experimental | The circuit training sessions conducted under the supervision of the researcher according to the following protocol:
1. Circuit training sessions conducted at 9:00 a.m., three times per week for 12 consecutive weeks.
2. Each session lasted approximately 30-40 minutes.
3. Sessions began with a 5-minute warm-up period.
4. The exercise circuit consisted of 6-8 stations combining aerobic and body-weight resistance exercises.
5. Activities included step-ups, jumping jacks, shuttle walking, sit-to-stand exercises, body-weight squats, balance activities, and modified push-ups.
6. Children performed each station for 30-60 seconds followed by 15-30 seconds of recovery.
7. The complete circuit repeated two to three times according to each child's tolerance and progression.
8. Exercise intensity maintained at moderate levels throughout training.
9. Participants continuously monitored for signs of fatigue, dizziness, hypoglycemia, or exercise intolerance.
10. Each session concluded with a 5-m Receives: Other: Group A |
| group B: Aerobic Training Program | Experimental | The aerobic training sessions conducted under the supervision of the researcher according to the following protocol:
1. Aerobic exercise sessions conducted at 9:00 a.m., three times per week for 12 consecutive weeks.
2. Each session lasted approximately 30-40 minutes.
3. Sessions began with a 5-minute warm-up consisting of stretching and light mobility exercises.
4. Participants performed continuous moderate-intensity aerobic activities including treadmill walking, brisk walking, jogging, and rhythmic movement exercises.
5. Exercise intensity maintained between 50-70% of age-predicted maximum heart rate.
6. Heart rate monitored throughout the training session to ensure participant safety.
7. Water breaks provided whenever needed.
8. Participants observed continuously for signs of fatigue, dizziness, hypoglycemia, or exercise intolerance.
9. Each session ended with a 5-minute cool-down period involving slow walking and stretching exercises. Receives: Other: Group B |
What is being measured
The primary outcome is the main question the study is designed to answer.
1. Fasting blood glucose level (mg/dL).
Fasting blood glucose level (mg/dL) was assessed following an overnight fast (≥8 hours). Blood glucose concentration was determined from venous blood samples using an automated biochemical analyzer. Changes in fasting blood glucose were evaluated to assess the intervention's effect on glycemic control.
Measured: 12 Weeks
Secondary outcomes (1)
Glycosylated Hemoglobin (HbA1c)
Glycosylated hemoglobin (HbA1c, %) was assessed from venous blood samples using standardized laboratory techniques. HbA1c reflects the mean blood glucose concentration during the previous 8 to 12 weeks and was used to evaluate the intervention's effect on long-term glycemic control.
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Oct 2026
- Study start22 Mar 2026
- Primary completion10 Nov 2026 (estimated)
- Study completion12 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetic ChildrenStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- Emad Eldin Mohamed
- Sponsor type
- University, hospital or other
- Collaborators
- Middle East University
- Responsible party
- Sponsor-investigator, Emad Eldin Mohamed, Middle East University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07874854
- Sponsor's protocol ID
- 987467
- Acronym
- Diabetic Child
- Status last verified
- Oct 2026
- First submitted
- 8 Oct 2026
- Last updated
- 15 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Differential Effects of Aerobic and Circuit Training on Glycemic Regulation in Diabetic Children
- ClinicalTrials.gov ID
- NCT07874854
- Acronym / sponsor ID
- Diabetic Child / 987467
- Conditions
- Diabetic Children
- Keywords
- Diabetic Children, Aerobic and Circuit Training
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Emad Eldin MohamedUniversity, hospital or other
- Collaborators
- Middle East University
- Study start
- 22 Mar 2026 (actual)
- Primary completion
- 10 Nov 2026 (estimated)
- Study completion
- 12 Dec 2026 (estimated)
- First posted
- 15 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Physical activity is recommended for children with type 1 diabetes mellitus (T1DM), yet uncertainty remains regarding the exercise modality that provides the greatest benefit for glycemic control. This study compared the effects of circuit training and aerobic training in children with T1DM.
Detailed description
Type 1 diabetes mellitus (T1DM) is a glucose homeostasis illness characterized by the autoimmune destruction of insulin-producing pancreatic β-cells, which gradually leads to insulin insufficiency and hyperglycemia. In addition to raising the risk of both immediate and long-term diabetes-related consequences, inadequate glycemic control throughout the formative years may negatively impact physical development, cardiovascular health, exercise capacity, and psychosocial well-being causing accelerated metabolic derangement, including hyperglycemia, ketoacidosis, hunger, and death (Katsarou et al., 2017). In order to restore and maintain euglycemia, therapy seeks to replicate the activity of the β-cell by exogenously substituting insulin and involves frequent blood glucose monitoring. Dr. Elliott P. Joslin, a visionary pioneer, believed that the best possible outcomes of T1DM treatment are achieved when both patients and families feel empod rather than victimized (Ogleet al., 2025). The prevalence of type 1 diabetes among individuals under the age of 20 in the United States is estimated to be 1.54 cases per 1,000 children. Non-Hispanic white children have the highest prevalence, with 2.0 cases per 1,000, which is 50% higher than black children (1.34 cases per 1,000) and twice as high as Hispanic children (1.0 cases per 1,000). T1DM affects both genders, unlike other autoimmune diseases that typically affect females (Patterson et al., 2019). Most studies have found a seasonal variation in onset in children, with the highest incidence of T1DM occurring in the winter and the lowest during the summer. This observation could be attributed to the greater incidence of viral infections during the winter months, which generate metabolic stress that surpasses the residual β-cell mass's ability to produce enough insulin to sustain euglycemia (Colberg et al., 2016). A susceptibility to T1DM begins at birth with the inheritance of genetic risk factors. Although the majority of newly diagnosed children have no family history of T1DM, unaffected children with a T1DM relative are at a higher risk than the general population. The most significantly related T1DM susceptibility genes are found in the major histocompatibility complex area of chromosome 6, where they most likely direct immune development and allow autoantigens to be presented to autoreactive lymphocytes (Riddell and Iscoe, 2006). The majority of pediatric patients with new-onset T1DM exhibit the characteristic signs of polyuria and polydipsia (69%), with polyphagia and weight loss appearing less commonly (33%). Patients and families usually report that symptoms persist 1 to 2 weeks, but sometimes for several months. These symptoms frequently worsen following an episode of enuresis or the onset of nocturia. Patients usually report vague complaints, such as tiredness, and may experience blurred vision (Yardley et al., 2013). In approximately one-quarter of instances, a patient with new-onset T1DM presents with diabetic ketoacidosis (DKA). These children initially exhibit the same basic signs (polyuria, polydipsia, polyphagia, and weight loss), which progressively worsen.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| group A: circuit training program | Experimental | Other: Group AThe circuit training sessions conducted under the supervision of the researcher according to the following protocol: 1. Circuit training sessions conducted at 9:00 a.m., three times per week for 12 consecutive weeks. 2. Each session lasted approximately 30-40 minutes. 3. Sessions began with a 5-minute warm-up period. 4. The exercise circuit consisted of 6-8 stations combining aerobic and body-weight resistance exercises. 5. Activities included step-ups, jumping jacks, shuttle walking, sit-to-stand exercises, body-weight squats, balance activities, and modified push-ups. 6. Children performed each station for 30-60 seconds followed by 15-30 seconds of recovery. 7. The complete circuit repeated two to three times according to each child's tolerance and progression. 8. Exercise intensity maintained at moderate levels throughout training. 9. Participants continuously monitored for signs of fatigue, dizziness, hypoglycemia, or exercise intolerance. 10. Each session concluded with a 5-m |
| group B: Aerobic Training Program | Experimental | Other: Group BThe aerobic training sessions conducted under the supervision of the researcher according to the following protocol: 1. Aerobic exercise sessions conducted at 9:00 a.m., three times per week for 12 consecutive weeks. 2. Each session lasted approximately 30-40 minutes. 3. Sessions began with a 5-minute warm-up consisting of stretching and light mobility exercises. 4. Participants performed continuous moderate-intensity aerobic activities including treadmill walking, brisk walking, jogging, and rhythmic movement exercises. 5. Exercise intensity maintained between 50-70% of age-predicted maximum heart rate. 6. Heart rate monitored throughout the training session to ensure participant safety. 7. Water breaks provided whenever needed. 8. Participants observed continuously for signs of fatigue, dizziness, hypoglycemia, or exercise intolerance. 9. Each session ended with a 5-minute cool-down period involving slow walking and stretching exercises. |
Who may qualify
- Ages
- 6 to 12 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (3 listed)
- ● Diabetic children aged 6-12 years.
Key exclusion criteria (1 listed)
- medical disorders such as cardiac, respiratory, renal, orthopedic, neurological, or other metabolic diseases that may interfere with participation in the exercise program.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Group Aaerobic training program in addition to routine medical care. | Other | group A: circuit training program |
| Group Baerobic training program in addition to the routine medical and nursing care provided by the diabetic clinic. | Other | group B: Aerobic Training Program |
Primary outcome
1. Fasting blood glucose level (mg/dL).
Time frame: 12 Weeks
Fasting blood glucose level (mg/dL) was assessed following an overnight fast (≥8 hours). Blood glucose concentration was determined from venous blood samples using an automated biochemical analyzer. Changes in fasting blood glucose were evaluated to assess the intervention's effect on glycemic control.
1 secondary outcome
Glycosylated Hemoglobin (HbA1c)
Time frame: 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2026.
Related trials for Diabetic Children
Not yet recruiting
Effectiveness of Coconut Oil Pulling and Moringa Mouthwash Versus Chlorhexidine in Reducing Gingivitis in Diabetic Children
Reducing Gingivitis, Clinical Effect
Recruiting
Pediatric Artificial Intelligence for Retinopathy Screening in Children With Type 1 Diabetes
Type 1 Diabetes Mellitus
RecruitingObservational study
Basic Hematological Parameters and Coagulation Profile in Type 1 Diabetic Children
Type 1 Diabetes Mellitus
RecruitingObservational study
Biomarkers of Acute Organ Injury in Pediatric Newly Diagnosed Type 1 Diabetes
Type 1 Diabetes Mellitus, Diabetic Ketoacidosis
RecruitingObservational study
General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery
Type 1 Diabetes, Celiac Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Group A and Group B in people with Diabetic Children, run by Emad Eldin Mohamed at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 15 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
1. Fasting blood glucose level (mg/dL). (time frame: 12 Weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2026.